Tuberculosis remains one of the leading infectious causes of mortality in the world, with approximately one-third of the population infected with mycobacteria (http://www.who.int /mediacentre/factsheets/fs104/en/). Pleural tuberculosis is the most common form of extrapulmonary tuberculosis and is one of the most relevant clinical pleural problems, characterized by accumulation of fluid and inflammatory cells in the pleural space, which occurs through a mechanism that is still not completely understood (13) .
The pleural space is a restricted environment that consists of a metabolically active monolayer of mesothelial cells involved in the maintenance of homeostasis, which becomes activated during pleural inflammation (4, 12) . Pleural mesothelial cells are able to initiate and regulate an innate response to Mycobacterium species infection by stimulating cytokine production as well as cell accumulation in the pleural cavity (12, 18, 19, 21) . Accumulation of inflammatory cells and T lymphocytes in pleural exudate is often observed as much in patients with tuberculous pleurisy (14) as in experimental infection (17, 20, 23, 30) . It is also known that pleural effusion derived from mycobacterial infection presents high numbers of type 1 cytokine producer lymphocytes in pleural fluid (13) . Even though the role of T lymphocytes in the immunopathogenesis of tuberculosis is well established, the mechanisms by which these cells accumulate and survive in the pleural effusion are not fully understood.
There are two different mechanisms by which T lymphocytes accumulate at inflammatory sites: migration (2) and local proliferation (8, 10) . Lymphocyte migration into inflammatory sites is facilitated by differential expression of adhesion molecules and homing receptors on T cells. Type 1 differentiated T lymphocytes upregulate, among other molecules, selectins and selectin ligands, which are related to increased migration of T cells into inflammatory sites (28) . However, accumulation of T lymphocytes in nonsecondary lymphoid organs can also occur through a mechanism that is independent of active migration and instead relies on local activation and proliferation (8, 15) .
In the present study, we investigate the mechanism by which T lymphocytes accumulate during mycobacterium infection, using a murine experimental model of pleurisy induced by BCG.
MATERIALS AND METHODS
Animals. Male C57BL/6 mice (15 to 20 g) were provided by the Oswaldo Cruz Foundation (Fiocruz, Brazil) Breeding Unit (Rio de Janeiro, Brazil). Animals were caged with free access to food and fresh water in a room with a temperature ranging from 22 to 24°C under a 12-h light/dark cycle at Farmanguinhos Experimental Animal Facility. All experimental procedures were performed according to guidelines provided by the Committee on Ethical Use of Laboratory Animals of the Oswaldo Cruz Foundation.
BCG-induced pleurisy. Mycobacterium bovis BCG was grown in Middlebrook 7H9 broth (Difco, Detroit, MI) supplemented with Middlebrook ADC (Difco). Pleurisy was induced by an intrathoracic (i.t.) injection of 100 l of 4.5 ϫ 10 5 CFU of BCG at middle-log growth phase, as previously described (17) . Control animals received an equal volume of sterile saline. Mice were sacrificed by excess amounts of CO 2 , and their thoracic cavities were washed with 1 ml of RPMI 1640 and 10 mM EDTA (Sigma-Aldrich, St. Louis, MO). Total leukocyte counts were determined with an automated particle counter (Beckman Coulter, Inc., Fullerton, CA). A Cytospin (Thermo Shandon, Waltham, MA) smear was performed with staining by the May-Grunwald-Giemsa method for differential leukocyte counts under light microscopy (100ϫ lens objective; Olympus). For CFU determination, cells recovered from pleural cavities were subjected to decontamination by the Petroff method before culture in Lowenstein-Jensen medium (31) .
Immunofluorescence staining and flow cytometric analysis. For flow cytometric analysis, cells recovered from pleural cavities were processed as described below. Samples of 10 6 cells were incubated in phosphate-buffered saline (PBS) plus 10% rat serum and 0.1% sodium azide (PBS-S; Sigma-Aldrich) and Fc␥IIR block monoclonal antibodies (MAbs) at 1:100 (CD16/CD32; BD Pharmingen, San Diego, CA) for 30 min at 4°C to avoid nonspecific background staining. After being blocked, cells were labeled with the appropriate concentration of MAb conjugated to fluorescein isothiocyanate (FITC) or phycoerythrin (PE; BD Pharmingen) diluted in PBS-S, and incubated for another 30 min at 4°C. After being labeled, cells were washed and resuspended in PBS-0.1% sodium azide for data acquisition with a FACSCalibur flow cytometer (BD Biosciences, Mountain View, CA). For intracellular c-Fos analysis, cells were first fixed with 4% paraformaldehyde (Sigma-Aldrich), and CD3 molecules were stained as described above. Cells were permeabilized in PBS-S-0.1% saponin (Sigma-Aldrich), incubated with rabbit anti-mouse c-Fos antibodies (Santa Cruz Biotechnologies, Inc., Santa Cruz, CA), and then stained with secondary FITC-conjugated anti-rabbit immunoglobulin G (IgG; Sigma-Aldrich). Apoptotic T lymphocytes were evaluated by concomitant detection of CD3 and 7-AAD staining. Briefly, after being blocked, cells were incubated with PBS-S containing 20 g/ml of 7-AAD and anti-mouse CD3-PE for 30 min at 4°C. Cells were then resuspended in 4% paraformaldehyde containing 20 g/ml of actinomycin for analysis. Forward scatter (FSC) and side scatter (SSC) parameters were set to exclude dead cells, and at least 10 4 lymphocytes were analyzed per sample. Control staining for determination of the positive population was performed based on an irrelevant IgG isotype labeled with FITC or PE. Once determined, quadrants were rigorously maintained for all analyses. Data analyses were performed using CellQuest software (BD Immunocytometry Systems, San Jose, CA).
Determination of cytokine production by ELISA. To evaluate interleukin-2 (IL-2) production in pleural wash fluids recovered after BCG-induced pleurisy, a standard sandwich enzyme-linked immunosorbent assay (ELISA) was performed in accordance with the manufacturer's instructions (BD Pharmingen). For production of gamma interferon (IFN-␥), tumor necrosis factor alpha (TNF-␣), or IL-12 p40 by nonrestimulated leukocytes recovered from saline-or BCGinjected mice (at 1, 7, and 15 days postinfection), cell ELISA was performed as previously described (5) . The plates were read at 490 nm on a Spectramax 190 (Molecular Devices).
Animal treatment. Fucoidan, a lectin-carbohydrate blocker (Sigma-Aldrich), was diluted in sterile saline and intravenously (i.v.) administered (10 mg/kg of body weight) 1 h before and 7 and 14 days after a single i.t. injection of BCG. Anti-mouse IL-2 (20 g/cavity; Pharmingen), anti-mouse IFN-␥ (20 g/cavity; R&D), or control (20 g/cavity) MAb was administered i.t. 4 days after BCGinduced pleurisy. At the indicated time points, the pleural cavities of the mice were washed and lymphocytes were evaluated by flow cytometry as described above.
Transwell migration assay. For transmigration assays, pleural wash fluids recovered from mice injected i.t. with saline (n ϭ 10) or BCG (n ϭ 15) were pooled after the thoracic cavities were washed with 500 l of saline. The pleural wash fluids were centrifuged (420 ϫ g for 10 min at 20°C), and saline and BCG cell-free supernatants (hereinafter referred to as SPW and BCG-PW, respectively) were recovered and kept at Ϫ80°C until use. Migration assays were performed with 24-well Transwell plates (Corning Costar) with 5-m-pore polycarbonate filters. Lymphocytes were enriched in a T-cell enrichment column (R&D Systems) and resuspended at a density of 3 ϫ 10 6 cells in assay buffer (Hanks balanced salt solution without Ca 2ϩ /Mg 2ϩ , containing 30 mM HEPES, 0.25% bovine serum albumin, pH 7.4). A cell suspension (200 l) was placed in the upper chamber, and 400 l of assay buffer or stimulus (SPW or BCG-PW) was placed in the lower chamber. After incubation for 4 h at 37°C, cells recovered from the lower chamber were counted, labeled as described above, and analyzed using a flow cytometer.
Transendothelial migration assay. A murine thymic endothelioma cell line (tEnd.1) was kindly provided by Thereza Christina Barja Fidalgo (Universidade do Estado do Rio de Janeiro, Brazil). These cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum containing 25 g/ml of gentamicin. Adherent cells were detached by washing them with PBS, followed by a 5-min incubation in a trypsin-EDTA solution at 37°C. tEnd.1 cells (2 ϫ 10 5 ) were cultured in Transwell polycarbonate culture inserts in 24-well culture plates (5.0-m pore diameter; BD Falcon, San Diego, CA) and allowed to grow to confluence for 48 h (37°C and 5% CO 2 ). Transwell inserts containing cultured monolayers were washed once in warm PBS and were added to 24-well culture plates containing 500 l of SPW, BCG-PW, or buffer. tEnd.1 monolayers were incubated with fucoidan (25 g/ml), anti-CD62P MAb (25 g/ml), anti-CD62E MAb (25 g/ml), or isotype control MAb (25 g/ml). Splenocytes were pretreated with anti-CD62L MAb (25 g/ml), fucoidan (25 g/ml), or isotype control MAb (25 g/ml). Pretreatments were performed 30 min prior to the assay. Splenocytes (3 ϫ 10 6 cells/well in 200 l of RPMI 1640) were added to the upper chamber of the Transwell tissue culture inserts, and the plate was incubated for 4 h at 37°C throughout the duration of the transmigration assay. Transmigrated cells were collected from the lower chamber, counted, and stained with antibodies against CD3, as described above.
Peripheral blood mononuclear labeling and adoptive transfer. Peripheral blood cells were subjected to double-density gradient centrifugation by the Histopaque-1119 and Histopaque-1077 (Sigma-Aldrich) methods to recover peripheral blood mononuclear cells. Cells were washed with sterile PBS and incubated with a 0.05-mg/ml solution of FITC (Sigma-Aldrich) for 30 min at 4°C. Cells were then washed, resuspended in sterile saline, and adoptively transferred into injected mice by an i.v. injection (4.5 ϫ 10 5 cells/mouse) (3). One hour after adoptive transfer, recipient mice received an i.t. injection of BCG or saline, and after 24 h, the FITC-labeled T lymphocytes recovered from the pleura were evaluated by flow cytometry (FACSCalibur). To evaluate the late lymphocyte accumulation, donor and recipient mice received an i.t. injection of BCG. On the 13th and 14th days after i.t. stimulation, recipient mice received FITC-labeled leukocytes recovered from donor mice on the 13th and 14th days, respectively. FITC-labeled T cells were set in the T-lymphocyte region determined by an FSC and SSC dot plot and confirmed by positive CD3 fluorescence staining.
Evaluation of proliferation. Splenocytes from normal C57BL/6 mice were incubated with 100 l of BCG-PW or SPW recovered from mice 7 days after i.t. injection (hereinafter referred to as day 7 BCG-PW or SPW, respectively) in the presence of one of the following MAbs (20-g/ml final concentration) (29): anti-mouse IL-2, anti-mouse IL-12 p40, anti-mouse TNF-␣, and anti-mouse IFN-␥ (R&D). Cell proliferation was evaluated using a CytoLite kit (Packard PerkinElmer, Wellesley, MA). Briefly, cells were incubated with solutions provided by the manufacturer, and proliferation was evaluated by determining counts per second of luminescence with Top Count NXT (Packard).
In vivo incorporation of BrdU. Lymphoproliferative cell numbers were determined as extensively described previously (24) . Briefly, mice were injected intraperitoneally daily with bromodeoxyuridine (BrdU) (1 mg/200 l of PBS per mouse), starting on the day of BCG infection and continuing for up to 7 days. The pleural cavities were then washed, and cells were stained with CD3-PE as described above. Cells were fixed and permeabilized with 4% paraformaldehyde-1% saponin and then frozen in 10% dimethyl sulfoxide and 90% fetal bovine serum to permeabilize the nuclear membrane overnight. Cells were then thawed, washed, resuspended in freshly prepared DNase I (4 units DNase/ml; Invitrogen) diluted in Hanks balanced salt solution with Ca 2ϩ and Mg 2ϩ , and incubated in a 37°C water bath for 1 h. Following DNase treatment, mouse anti-BrdU was added, followed by FITC-conjugated anti-mouse IgG. Cells were than washed and acquired with a FACSCalibur flow cytometer as described above.
Statistical analysis. Statistical significance was assessed by analysis of variance followed by the Newman Keuls t test. Results are expressed as means Ϯ standard errors of the means (SEM), and the significance level in all cases was set at P values of Ͻ0.05.
RESULTS
Kinetics of lymphocyte accumulation during BCG-induced pleurisy. Fig. 1A shows an initial peak of T-lymphocyte accumulation 1 day after i.t. injection of BCG, followed by a significant decrease in cell numbers within 48 h. After this time point, Tlymphocyte accumulation started to increase again until 15 days after BCG injection. Similar profiles were observed for CD4 ϩ and CD8 ϩ T-lymphocyte accumulation ( Fig. 1B and C) . It is interesting to note that ␥␦ ϩ T-lymphocyte accumulation in the pleural cavities of BCG-infected mice was significantly different from that for the control mice between 1 and 15 days after BCG i.t. injection, despite a small decrease of ␥␦ ϩ T lymphocytes at 48 h (Fig.  1D ). Concerning T-lymphocyte decrease 48 h after BCG infection, the numbers of apoptotic cells in the pleural cavities of VOL. 76, 2008 T
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36-h-infected mice were evaluated. The representative dot plots demonstrate increases in numbers of T cells stained with 7-AAD 36 h after BCG i.t. injection relative to the numbers for the control group (Fig. 1E) . The lymphocyte numbers were in inverse proportion to the numbers of CFU detected in pleural wash fluids recovered from BCG-injected mice. As shown in Fig. 1F , high levels of bacterial load were observed at 1 day, followed by decreases in colony counts until 15 days, after BCG i.t. injection.
Production of type 1 cytokines by leukocytes recovered from the pleural cavities of BCG-injected mice. Several studies have demonstrated the production of type 1 cytokines as well as their role in a pulmonary experimental model of Mycobacterium species infection (2). Figure 2 shows the evaluation of (Fig. 2) . IFN-␥ production was sustained from 1 until 15 days postinfection ( Fig. 2A) , whereas increased levels of IL-12 p40 and TNF-␣ were detected in supernatants of leukocytes recovered at 1 and 15 days postinfection but not in those of leukocytes recovered at 7 days postinfection ( Fig. 2C and D) . Interestingly, an increase in IL-2 production accompanied the infection's time course (Fig. 2B) . Production of the type 2 cytokine IL-5 was also detected at 1 day, but not at 7 or 15 days, after BCGinduced pleurisy (data not shown). Selectin blockade in BCG-injected mice. Selectins are crucial for leukocyte migration into inflammatory sites (15, 29) . In this context, we pretreated mice with fucoidan, a blocker of lectincarbohydrate interaction that is able to impair selectin-dependent cell migration (26) . Blockade of lectin-carbohydrate interaction failed to inhibit total leukocyte migration 1 day after induction of pleurisy (Fig. 3A) , even though it inhibited neutrophil migration to basal levels (2.69 ϫ 10 6 Ϯ 0.35 ϫ 10 6 [BCG] versus 1.43 ϫ 10 6 Ϯ 0.34 ϫ 10 6 [fucoidan] neutrophils/cavity; P Ͻ 0.05) and inhibited T-lymphocyte accumulation in the pleural cavity 1 day after i.t. injection of BCG (Fig. 3B) .
Selectin blockade for 15 days after BCG infection failed to inhibit total leukocyte accumulation in the pleural cavities of BCG-injected mice (Fig. 3A) . Similarly, fucoidan treatment did not modify BCG-induced mononuclear cell accumulation (5.1 ϫ 10 6 Ϯ 0.5 ϫ 10 6 [BCG] versus 4.6 ϫ 10 6 Ϯ 0.6 ϫ 10 6
[fucoidan] mononuclear cells/cavity; P Ͼ 0.05) or T-lymphocyte accumulation (Fig. 3B) . In contrast, BCG-induced neutrophil influx into the pleural cavities of mice was significantly inhibited by fucoidan pretreatment 15 days after pleurisy induction (1.95 ϫ 10 6 Ϯ 0.21 ϫ 10 6 [BCG] versus 1.09 ϫ 10 6 Ϯ 0.1 ϫ 10 6 [fucoidan] neutrophils/cavity; P Ͻ 0.05). To evaluate whether fucoidan pretreatment was modifying T-lymphocyte activation, we measured cytokine production by leukocytes recovered from BCG-stimulated mice. Fucoidan treatment did not alter cytokine production by total leukocytes recovered from the pleural cavities of BCG-injected mice, as demonstrated by TNF-␣, IL-12 p40, and IFN-␥ detection 15 days after infection (Fig. 3C) . T-lymphocyte migration into the inflammatory site. We further investigated the abilities of BCG-PW and SPW recovered from i.t. injected mice to promote cell migration in vitro. Using a Transwell model, we observed that BCG-PW recovered 1 day after BCG injection was able to induce CD3 ϩ T-cell migration (Fig. 4A) . In contrast, day 7 and 15 BCG-PW failed to induce in vitro T-cell chemotaxis, suggesting that the T-lymphocyte migration observed 7 and 15 days after BCG stimulation did not depend on local production of chemoattractant mediators. As an additional control, we spiked the SPW with BCG (3 ϫ 10 3 CFU/well) and did not observe lymphocyte migration. We further investigated the involvement of L-, P-, and E-selectins in day 1 BCG-PW-induced T-cell migration by using a transendothelial assay. CD3 ϩ T lymphocytes migrated more strongly toward day 1 BCG-PW than to SPW or SPW spiked with BCG, a phenomenon that was inhibited by pretreatment of splenocytes with anti-L-and anti-P-selectin MAbs (Fig. 4B) . CD3 ϩ T migration was also inhibited when endothelial cells were pretreated with anti-E-selectin MAb. It is worth noting that day 7 and 15 BCG-PW failed to induce CD3 T-lymphocyte migration throughout the endothelial cell monolayer, which was unchanged by preincubation of cells with anti-selectin MAbs (data not shown). Therefore, we performed an assay of adoptive transfer of FITC-labeled leukocytes into BCG-or saline-stimulated mice. Figure 4C shows that 1 day after BCGstimulation, adoptively transferred T lymphocytes labeled with 
Role of IL-2 and IFN-␥ in BCG-induced late lymphocyte accumulation.
Since late T-lymphocyte accumulation was not a consequence of cell migration, we evaluated the ability of cytokines present in the pleural fluid to promote T-cell proliferation. ϩ T lymphocytes were determined with an FSC and SSC dot plot and confirmed by positive CD3 fluorescence staining. The effect of fucoidan treatment on cytokine production in the mouse pleural cavity 15 days after BCG-induced pleurisy is shown in panel C. Cytokine production was evaluated by ELISA as described in Materials and Methods. Results are expressed as means Ϯ SEM for groups of at least six animals each in four different experiments. Statistically significant differences (P Ͻ 0.05) between control and BCG-stimulated groups are indicated by asterisks, and ϩ represents differences between treated and untreated groups.
FIG. 4. (A)
In vitro migration of enriched T lymphocytes toward SPW or BCG-PW recovered from mice i.t. injected 1 day, 7 days, or 15 days before. SPW spiked with BCG (3 ϫ 10 3 CFU/well) was used as assay control. Spleen leukocytes were placed in the upper chamber of 5.0-m-pore-diameter Transwell inserts, and cells that migrated into the bottom chamber were recovered and labeled for CD3. (B) In vitro migration of T lymphocytes toward day 1 SPW or BCG-PW. T cells were pretreated with anti-mouse-CD62L or anti-mouse-CD62P, while endothelial cells were pretreated with anti-mouse-CD62E. T cells and endothelial cells pretreated with the isotype control as well as SPW spiked with BCG (3 ϫ 10 3 CFU/well) were used as an assay control. Cell migration was evaluated as described above. (C) Accumulation of FITC-labeled lymphocytes in the pleural cavities of BCG-injected mice. FITC-labeled T cells were set in the lymphocyte region, determined with an FSC and SSC dot plot, and confirmed by positive CD3 fluorescence staining. Results are expressed as means Ϯ SEM for groups of at least five animals each, and each experiment was repeated twice. Statistically significant differences (P Ͻ 0.05) between control and BCG-stimulated groups are indicated by asterisks, and ϩ represents differences between treated and untreated groups.
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Splenocytes from normal animals were stimulated by day 7 BCG-PW or SPW. Splenocytes were incubated with BCG-PW or SPW either in the absence or in the presence of antibodies against different cytokines, and proliferation was evaluated by luminescence using a CytoLite kit. Figure 5A shows that BCG-PW was able to induce T-lymphocyte proliferation similarly to ConA. In contrast, SPW was a weak proliferative stimulus, comparable to the negative control (RPMI). Pretreatment with MAbs against IL-2, IFN-␥, or IL-12 p40 significantly inhibited the proliferative effect of BCG-PW, while treatment with MAbs against TNF-␣ did not impair T-lymphocyte proliferation. It is important to note that BCG-PW recovered from mice injected 1 day before did not induce T-lymphocyte proliferation (data not shown) and that the addition of isotype control MAb did not affect T-lymphocyte proliferation (Fig. 5A) . In agreement, in vivo treatment with BrdU demonstrated high levels of lymphoproliferation through BrdU incorporation by CD3 ϩ cells in mice that had received an i.t. injection of BCG 7 days before ( Fig. 5B and D) . These data were confirmed by in vivo IL-2 or IFN-␥ neutralization prior to BCG stimulus, by inhibiting T-lymphocyte accumulation in the mouse pleural cavity 7 days after pleurisy induction (Fig. 5C) . Accordingly, neither IL-2 nor IFN-␥ induced T-lymphocyte migration in vitro (data not shown).
Evaluation of molecules involved in lymphocyte proliferation. A high rate of IL-2 in situ activates T cells and induces IL-2 receptor-dependent downstream pathways, resulting in c-Fos expression (33) . Therefore, we analyzed the involvement of IL-2R/CD25 and c-Fos in the T-lymphocyte proliferative response. Figure 6A shows a significant increase in the expression of CD25 in pleural CD3 ϩ T lymphocytes recovered 7 days after BCG i.t. stimulation ( Fig. 6A and B ). These cells also show an increase in c-Fos expression relative to the level for the control group (Fig. 6C and D) .
DISCUSSION
In this study, we demonstrate the mechanisms of T-lymphocyte accumulation at different time points of the pleural inflammatory reaction induced by i.t. injection of BCG. The importance of T-lymphocyte accumulation at mycobacteriuminfected sites is crucial in both mouse and human pulmonary tuberculoses. T cells comprise more than 70% of total leukocytes in tuberculous pleural effusions (32) , in which CD4 ϩ and CD8 ϩ T cells are essential for effective control of Mycobacterium tuberculosis infection (6) . We demonstrate increases of ␥␦ ϩ T-lymphocyte numbers in the pleural cavities of mice that received an i.t. injection of BCG 1 day after infection, which remained augmented up to 15 days after infection. It is worth noting that this profile is different from the biphasic profiles observed for CD4 ϩ and CD8 ϩ T-lymphocyte accumulation in BCG-injected mice, in which T-cell numbers increased on day 1, returned to basal levels no later than day 2, and then in- Recently, it was demonstrated that cells recovered from patients with pleural effusion due to tuberculosis infections are able either to undergo apoptosis or to proliferate when stimulated with mycobacterial antigens in vitro (9) . It is worth noting that we observed an increase in T-cell death after BCG stimulation within 36 h, contributing to the decrease in T-cell numbers at 48 h. Despite the fact that the role of T cells is well described for immune reactions induced by mycobacterium infection, the mechanisms by which these cells accumulate at the infectious sites have not yet been clarified, especially for tuberculous pleural effusions. We first analyzed whether T lymphocytes were recruited into the pleural site by the classical mechanism of leukocyte migration through adhesion molecules. The crucial role of selectins in inducing T-lymphocyte migration in other airway inflammatory models has been demonstrated (1); however, most studies concerning the role of selectin in mycobacterial infections are restricted to phenotyping T lymphocytes and, so far, do not provide evidence that such adhesion molecules are involved in T-lymphocyte migration and accumulation in pleural effusion (29) .
The inhibition of selectin by fucoidan pretreatment diminished the acute accumulation of T lymphocytes in the pleural cavities of infected mice, suggesting that these cells are actively migrating to the inflammatory site. It is interesting to note that repeated treatment with fucoidan did not inhibit the T-lymphocyte numbers and cytokine production at 15 days postinfection, whereas the neutrophil migration observed at 15 days postinfection was inhibited, demonstrating the efficacy of selectin blockade by fucoidan and suggesting that this treatment is not able to interfere with lymphocyte activation. These results were corroborated with in vitro transmigration assays using specific antibodies against L-, P-, or E-selectins and in vivo adoptive transference of lymphocytes that showed an active migration of T lymphocytes at 1 day but not at 15 days postinfection.
In fact, selectins seem to be involved in leukocyte migration during a mycobacterially induced immune response (16) . Recently, using an experimental model of pulmonary tuberculosis, Schreiber and coworkers (25) demonstrated that although the initial lymphocyte accumulation in lung granuloma 21 days after M. tuberculosis infection is dependent on selectin ligands, chronic-phase cell-mediated immune responses depend not on selectins but probably on organized neolymphoid structures within the lungs.
In agreement with those findings, we also demonstrated that splenic T lymphocytes proliferate when cultured with pleural fluid from BCG-infected mice and that the addition of MAbs to neutralize IL-2 and IFN-␥ impaired the lymphoproliferative response. However, such effects were not observed when splenocytes were cultured with BCG-PW and treated with MAbs to block TNF-␣. Since IL-12 is not involved in lymphocyte proliferation but is involved in IFN-␥ production, the lack of proliferation observed in splenocytes treated with antimouse-IL-12 represents an indirect effect of IFN-␥ activity. In fact, such results are in accordance with the in vivo observa- on September 12, 2017 by guest http://iai.asm.org/ tions that pleural T cells incorporate BrdU at the site of infection and that both IL-2 and IFN-␥ are necessary to induce T-lymphocyte accumulation during BCG-induced pleurisy in a mechanism that does not depend on T-cell migration. Accordingly, in vitro studies demonstrated that pleural mononuclear cells stimulated with M. tuberculosis proliferate in the presence of type 1 cytokines (9). Indeed, IFN-␥ has been shown to induce T-cell proliferation (7) . Such an effect relies on the density of IFN-␥R2 expression on the T-cell membrane, a phenomenon modulated by the presence of growth factors such as IL-2 (22) . Moreover, activation of IL-2␤ chain receptor on effector and memory T lymphocytes induces proliferation without the requirement of antigen presentation (11) . Accordingly, T lymphocytes present in the mouse pleural cavities 15 days after BCG i.t. injection expressed high levels of IL-2␣ receptor (CD25), in addition to increased expression of the AP-1 component c-Fos, indicating a proliferative phenotype. Taken together, our results demonstrate that T-lymphocyte accumulation at early time points after mycobacterial infection is due to migration from the bloodstream to the inflammatory site, while at late time points of BCG-induced pleurisy, Tlymphocyte accumulation depends not on migration but on local proliferation facilitated by IL-2 and IFN-␥ present in the pleural cavity.
